WBA $11.98 most active on NASDAQ 18 Mar 2026: Track volume spike and analyst outlook

WBA stock closed at $11.98 on NASDAQ in the United States on 18 Mar 2026 after an outsized trading day. Volume hit 452,081,061 shares versus an average of 16,940,296, making Walgreens Boots Alliance one of the most active names today. The price sits between the 50-day average $11.66 and the 200-day average $10.81. We use market and financial data to connect the volume surge to valuation, liquidity, and near-term catalysts. Meyka AI provides additional model-based context and a proprietary grade in the analysis below.

WBA stock trading snapshot and why volume matters

Walgreens Boots Alliance (WBA) closed at $11.98 on NASDAQ with 452,081,061 shares traded. The day’s relative volume was 26.69, a clear liquidity spike. High volume confirms investor attention and can accelerate short-term price moves. Today’s volume likely reflects index-level changes and renewed attention after inclusion in the Dow, per market coverage Investors Business Daily.

WBA stock fundamentals and valuation metrics

Walgreens Boots Alliance reports EPS -7.29 and a PE of -1.64, reflecting negative trailing earnings. Price-to-sales is 0.09, and price-to-book is 1.44. The company pays a dividend of $0.25 per share for a 2.09% yield. These metrics show deep leverage to any earnings recovery and a low valuation relative to sales but high balance-sheet leverage.

WBA stock technicals and short-term levels

Technical indicators show the 50-day average $11.66 and the 200-day average $10.81. Year high is $13.25 and year low is $8.08. Momentum readings include RSI at 100.00 and ATR $0.16, signaling strong short-term buying pressure. A close above $12.50 would test the year high as resistance. Traders should watch the high volume for follow-through or quick mean reversion.

Meyka AI rates WBA with a score out of 100 and the grade explained

Meyka AI rates WBA with a score out of 100: 59.48 (Grade C+, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score blends valuation, cash-flow metrics, and a mixed company rating that flags leverage and negative earnings against attractive price-to-sales.

Catalysts, analyst signals, and recent news impact

Recent coverage highlights Walgreens’ role in the Dow and investor focus on retail pharmacy positioning. The upgrade/downgrade consensus shows limited analyst coverage and a weak sentiment score. News flow can move WBA stock quickly given the current low float turnover and heavy intraday volume. For more market commentary see Seeking Alpha analysis pages for broader investor views Seeking Alpha.

Risks, opportunities, and sector context for WBA stock

Risks include high debt ratios with debt-to-equity at 4.04 and negative operating margins. Free cash flow per share is -0.59. Opportunities come from stable retail foot traffic, pharmacy margins, and potential cost actions. In the Healthcare sector, Walgreens’ pharmacy retail model can benefit from defensive flows during market weakness.

Final Thoughts

Key takeaways for WBA stock: the share price closed at $11.98 on NASDAQ on 18 Mar 2026 with extraordinary volume 452,081,061, making it one of the day’s most active symbols. Fundamentals show negative EPS -7.29, a negative PE -1.64, and elevated leverage. Technical resistance sits near the year high $13.25; a conservative 12-month price target of $12.50 implies a modest upside of 4.34% from today’s close. Meyka AI’s forecast model projects $4.08, implying a downside of -65.96% versus the current price; forecasts are model-based projections and not guarantees. Meyka AI’s grade C+ (59.48) frames WBA as a HOLD based on mixed financials and sector positioning. Investors should weigh high intraday liquidity and sector defensiveness against weak profitability and heavy debt before taking new positions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.